Report Shows Byetta, Januvia and Other Incretin Mimetic Drugs for Type...
According to the Institute for Safe Medication Practices’ most recent QuarterWatch report, incretin mimetic drugs such as Byetta, Januvia and Victoza may be 25 times more likely to be linked to...(PRWeb April 19, 2013)Read the full story at http://www.prweb.com/releases/Byetta-Januvia-cancer/04/prweb10653663.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 23, 2013 Category: Pharmaceuticals Source Type: news

Invokana Tops Januvia as Third-Line Therapy, With DrawbacksInvokana Tops Januvia as Third-Line Therapy, With Drawbacks
In patients with type 2 diabetes not controlled with metformin plus sulfonylurea, adding canagliflozin provided better glucose control than adding sitagliptin, but with increased genital infections. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 16, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Sun Pharma gets FDA nod for generic version of Januvia
This comes as a surprise as Sun has partnered the US based MSD in the domestic market to sue Glenmark for the patent infringement on the same drug. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 15, 2013 Category: Pharmaceuticals Source Type: news

Research suggests popular diabetes drugs can cause abnormal pancreatic growth in humans
Individuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida. Their findings were published online March 22 in the journal Diabetes.   The researchers, from the Larry L. Hillblom Islet Research Center at UCLA and the Diabetes Center at the University of Florida, found that cell mass was increased approximately 40 percent in the pancreases of deceased organ donors who had Type 2 ...
Source: UCLA Newsroom: Health Sciences - March 26, 2013 Category: Universities & Medical Training Source Type: news

FDA studies possible pre-cancerous link with diabetes drugs
(Reuters) - The U.S. Food and Drug Administration is studying unconfirmed reports that a widely used class of diabetes drugs, which includes Merck & Co's Januvia, may cause inflammation of the pancreas and pre-cancerous changes to the pancreas. (Source: Reuters: Health)
Source: Reuters: Health - March 14, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Some Diabetes Drugs Linked To Pancreatitis Risk
Diabetes patients who take the newest class of diabetes drugs have double the risk of being hospitalized with acute pancreatitis, researchers from Johns Hopkins University School of Medicine, Baltimore, reported in JAMA Internal Medicine. The authors explained that the new forms of sugar-control medications prescribed to diabetes patients are called GLP-1 (glucagon-like peptide-1). Examples of such drugs include sitagliptin (Januvia) and exenatide (Byetta)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 1, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news

The Confusion Over A Pair Of Diabetes Drugs And Pancreatitis
Will yet another study about the risk of pancreatitis spell trouble for some diabetes drugs? The latest instance involves a paper that was published in JAMA Internal Medicine and indicates that Merck’s Januvia and Bristol-Myers Squibb’s Byetta can double the risk of developing pancreatitis. Yes, this is the same issue that, over the past few years, has plagued drugs that increase the GLP-1 hormone. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 1, 2013 Category: Pharmaceuticals Authors: Ed Silverman Source Type: news

Editorial: GLP-1 based agents and acute pancreatitis
Source: BMJ Area: News The author of this BMJ editorial discusses a recent study published in JAMA which found that the glucagon-like peptide (GLP)-1-based therapies sitagliptin and exenatide were associated with increased odds of hospitalisation for acute pancreatitis. According to the author, the FDA database carried a signal for acute pancreatitis with exenatide in 2006, a year before the agency alerted clinicians. He states, "Furthermore, all GLP-1 based agents that have been on the market for more than two years have also generated a signal for acute pancreatitis, suggesting a class effect." The regulatory procedures...
Source: NeLM - News - February 28, 2013 Category: Drugs & Pharmacology Source Type: news

The Law Firm of d'Oliveira & Associates Now Offers a No Win -...
Law Firm Offers a No Win - No Fee Promise for alleged clients injured from the oral insulin medication, Januvia, used to treat Type 2 Diabetes. Januvia has been linked to side effects, such as...(PRWeb February 25, 2013)Read the full story at http://www.prweb.com/releases/2013/2/prweb10460572.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 26, 2013 Category: Pharmaceuticals Source Type: news

Sitagliptin and exenatide associated with an increased risk of acute pancreatitis
Source: JAMA Internal Medicine Area: News According to a study published in JAMA Internal Medicine, treatment of type 2 diabetes mellitus with the glucagon-like peptide (GLP)-1-based therapies sitagliptin and exenatide was associated with increased odds of hospitalisation for acute pancreatitis.   A large administrative database in the United States  was used to collect data for the  population-based case-control study - adults with type 2 diabetes mellitus aged 18 to 64 years were identified and 1269 hospitalised cases with acute pancreatitis using a validated algorithm and 1269 control subjects matche...
Source: NeLM - News - February 26, 2013 Category: Drugs & Pharmacology Source Type: news

Newest Diabetes Drugs Linked to Higher Pancreatitis Risk
Patients on Januvia, Byetta twice as likely to develop condition, study says Source: HealthDay Related MedlinePlus Pages: Diabetes Medicines, Pancreatitis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 25, 2013 Category: Consumer Health News Source Type: news

Glucagonlike Peptide 1-Based Therapies Associated With Acute Pancreatitis In Study
JAMA Internal Medicine Study Highlights In a study by Sonal Singh, M.D., M.P.H., of The Johns Hopkins University School of Medicine, Baltimore, and colleagues, treatment with the glucagonlike peptide-1 (GLP-1)-based therapies sitagliptin and exenatide were associated with increased odds of hospitalization for acute pancreatitis in adults with type 2 diabetes mellitus. (Online First) The population-based case-control study used a large administrative database of adults with type 2 diabetes. Researchers identified 1,269 hospitalized cases with acute pancreatitis and 1,269 matched controls... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 25, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news

Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results
Dateline City:  WHITEHOUSE STATION, N.J. 2012 Full-Year Non-GAAP EPS of $3.82, Excluding Certain Items; GAAP EPS of $2.16; Fourth-Quarter Non-GAAP EPS of $0.83, Excluding Certain Items; GAAP EPS of $0.46 2012 Full-Year Worldwide Sales Were $47.3 Billion, a Decrease of 2 Percent, Including a 3 Percent Unfavorable Impact from Foreign Exchange; Fourth-Quarter Worldwide Sales Were $11.7 Billion, a Decline of 5 Percent, Including a 2 Percent Unfavorable Impact...
Source: Merck.com - Corporate News - February 1, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Corporate News Financial News Source Type: news